Arca
Skip to content
Tools
Tools

VEGFA: Vascular endothelial growth factor A, long form

[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A.

  • Drugs that act on it: 13
  • Approved: 7
  • In phases 1 to 3: 5
  • Sponsors: 8

Who is on it, and how far along

Every drug ChEMBL records acting on VEGFA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 7
  • Protein or peptide 3
  • Other 2

Approved7

  • Bevacizumab
  • Aflibercept
  • Bevacizumab gamma
  • Ranibizumab
  • Faricimab
  • Brolucizumab
  • Pegaptanib sodium

Phase 34

  • Conbercept
  • Abicipar pegol
  • Muparfostat
  • Pegaptanib octasodium

Phase 21

  • Vanucizumab

Phase 10

    Preclinical or unknown1

    • Bevacizumab 111IN

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Ollin Biosciences, Inc.215%
    • Cellxpert Biotechnology Corp.18%
    • Chengdu Kanghong Biotech Co., Ltd.18%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 10 of 13 act as: Vascular endothelial growth factor A inhibitor; the rest name their own mechanism.
    BevacizumabApprovedQilu Pharmaceutical (Hainan)AntibodyInhibitor895
    AfliberceptApprovedOllin Biosciences, Inc.Protein or peptideInhibitor101
    Bevacizumab gammaApproved—AntibodyBinding agentVascular endothelial growth factor A binding agent43
    RanibizumabApprovedOllin Biosciences, Inc.AntibodyInhibitor33
    FaricimabApprovedRocheAntibodyInhibitor32
    BrolucizumabApprovedNovartis PharmaceuticalsAntibodyInhibitor4
    Pegaptanib sodiumApprovedBausch & LombSmall moleculeAntagonistVascular endothelial growth factor A antagonist0
    ConberceptPhase 3Chengdu Kanghong Biotech Co., Ltd.Protein or peptideInhibitor6
    Abicipar pegolPhase 3AbbVieProtein or peptideInhibitor0
    MuparfostatPhase 3Cellxpert Biotechnology Corp.OtherInhibitor0
    Pegaptanib octasodiumPhase 3Novartis PharmaceuticalsOtherInhibitor0
    VanucizumabPhase 2RocheAntibodyInhibitor0
    Bevacizumab 111INPreclinical or unknown—AntibodyBinding agentVascular endothelial growth factor A binding agent0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 46 in all, from ClinicalTrials.gov.
    Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PEDAfliberceptPhase 4Not yet recruitingHonghua Yu,MDNov 17, 2026
    A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal CancerBevacizumabPhase 2Not yet recruitingKorea University Anam HospitalNov 17, 2026
    Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular EdemaBrolucizumabNot applicableNot yet recruitingThe Fourth Affiliated Hospital of Zhejiang University School of MedicineNov 13, 2026
    Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsBevacizumabPhase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.Nov 12, 2026
    Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF MutationBevacizumabPhase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineNov 9, 2026
    Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)FaricimabPhase 3Not yet recruitingUniversity of Illinois ChicagoNov 6, 2026
    Efficacy of Aflibercept With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm.Aflibercept—Not yet recruitingNew Valley UniversityNov 6, 2026
    Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After ResectionBevacizumabPhase 2RecruitingFudan UniversityNov 4, 2026
    A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerBevacizumabPhase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 4, 2026
    Novel endOvascular Therapy With beVAcizumab and Cannabinoids for GlioblastomaBevacizumabPhase 1Not yet recruitingUnity Health TorontoNov 2, 2026
    A Study of BON-C1393 in Adults With Advanced Solid TumorsBevacizumabPhase 1Not yet recruitingBeOne MedicinesOct 29, 2026
    Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular CarcinomaBevacizumab—Not yet recruitingAssiut UniversityOct 29, 2026
    VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyAfliberceptPhase 2Not yet recruitingUniversity of MiamiOct 23, 2026
    A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).AfliberceptPhase 3Recruiting4D Molecular TherapeuticsOct 9, 2026
    Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.RanibizumabPhase 4Not yet recruitingSoutheast Retina Center, GeorgiaOct 7, 2026
    A Study to Compare GNR-139 and Eylea® in Patients With nAMDAfliberceptPhase 3RecruitingAO GENERIUMSep 28, 2026
    Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)AfliberceptPhase 3Not yet recruitingOllin Biosciences, Inc.Sep 25, 2026
    Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)AfliberceptPhase 3Not yet recruitingOllin Biosciences, Inc.Sep 25, 2026
    Changes in Intraocular Pressure After Intravitreal InjectionRanibizumab—Not yet recruitingAssiut UniversitySep 17, 2026
    Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective StudyAflibercept, Ranibizumab—RecruitingAbdulkadir KüçükSep 15, 2026
    Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)RanibizumabPhase 3Not yet recruitingOllin Biosciences, Inc.Sep 11, 2026
    South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)FaricimabPhase 4Not yet recruitingBirmingham and Midland Eye Centre Sandwell and west Birmingham NHS trustAug 7, 2026
    LEAP Strategy for Neovascular Age-Related Macular DegenerationFaricimab, Conbercept, RanibizumabNot applicableNot yet recruitingChinese PLA General HospitalAug 4, 2026
    A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut MicrobiotaConberceptNot applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang UniversityJul 22, 2026
    Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical AnesthesiaRanibizumab—RecruitingMinia UniversityJul 14, 2026
    A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis SyndromeFaricimabPhase 4RecruitingCincinnati Eye Institute, Southwest OhioJul 10, 2026
    Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyRanibizumabPhase 3RecruitingSANGMYUNG innovationJul 10, 2026
    Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled TrialFaricimabPhase 2Not yet recruitingSingapore National Eye CentreJul 2, 2026
    Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)Faricimab—Not yet recruitingSun Yat-sen UniversityMay 12, 2026
    Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabFaricimab, RanibizumabNot applicableRecruitingOsijek University HospitalApr 9, 2026
    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyBevacizumab gammaPhase 2RecruitingNational Cancer Institute (NCI)Apr 1, 2026
    Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and SafetyFaricimabNot applicableActive, not recruitingJakkrit JuhongMar 18, 2026
    Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialBevacizumab gammaPhase 2RecruitingCity of Hope Medical CenterDec 17, 2025
    Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT TrialBevacizumab gammaPhase 3RecruitingCity of Hope Medical CenterDec 9, 2025
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerBevacizumab gammaPhase 3RecruitingNational Cancer Institute (NCI)Sep 30, 2025
    Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialBevacizumab gammaPhase 3RecruitingNRG OncologySep 10, 2025
    Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion TreatmentConberceptPhase 4RecruitingFirst Affiliated Hospital of Chongqing Medical UniversityAug 21, 2025
    Aqueous Humor Proteome in Retinal Vein Occlusion With Macular EdemaConbercept—Active, not recruitingTianjin Medical University Eye HospitalAug 6, 2025
    Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 MicronsBrolucizumabPhase 3RecruitingBelfast Health and Social Care TrustMay 22, 2025
    Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyConberceptNot applicableRecruitingWang YushengDec 5, 2024
    Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerBevacizumab gammaPhase 1RecruitingNational Cancer Institute (NCI)Nov 20, 2024
    Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerBevacizumab gammaPhase 3RecruitingNRG OncologyAug 30, 2024
    External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerBevacizumab gammaPhase 1 / Phase 2RecruitingJonsson Comprehensive Cancer CenterAug 9, 2024
    Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular EdemaBrolucizumabPhase 4Active, not recruitingGuangdong Provincial People's HospitalJul 12, 2024
    Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyConberceptPhase 4Active, not recruitingShanghai Eye Disease Prevention and Treatment CenterMar 12, 2024
    Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDBrolucizumabNot applicableActive, not recruitingBerner AugenklinikJun 21, 2021

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Non-small cell lung carcinoma
    0.63
    Macular retinal edema
    0.62
    Breast neoplasm
    0.60

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1783, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P15692, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.